What is William Blair’s Estimate for Amgen FY2026 Earnings?

Amgen Inc. (NASDAQ:AMGN) – Analysts at William Blair raised their FY2026 EPS estimates for shares of Amgen in a research note issued to investors on Monday, July 14th. William Blair analyst M. Phipps now anticipates that the medical research company will earn $21.67 per share for the year, up from their prior forecast of $21.62. William Blair has a “Outperform” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share.

AMGN has been the subject of several other reports. Guggenheim assumed coverage on shares of Amgen in a report on Tuesday, May 20th. They set a “neutral” rating and a $288.00 price objective for the company. Erste Group Bank lowered Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 8th. Royal Bank Of Canada cut their price objective on Amgen from $324.00 to $320.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. Wall Street Zen upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 18th. Finally, UBS Group reiterated a “neutral” rating and issued a $315.00 price target (down from $319.00) on shares of Amgen in a report on Friday, May 2nd. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $307.82.

Amgen Stock Down 1.5%

Shares of NASDAQ:AMGN opened at $292.51 on Tuesday. The firm has a market cap of $157.29 billion, a PE ratio of 26.69, a price-to-earnings-growth ratio of 2.68 and a beta of 0.49. The company has a fifty day simple moving average of $284.34 and a 200 day simple moving average of $288.57. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70. Amgen has a 12-month low of $253.30 and a 12-month high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The firm had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. During the same quarter last year, the firm earned $3.96 EPS. Amgen’s quarterly revenue was up 9.4% on a year-over-year basis.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in AMGN. Capital World Investors increased its stake in Amgen by 1,292.0% during the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company’s stock valued at $1,693,042,000 after buying an additional 6,029,058 shares during the period. Norges Bank bought a new position in shares of Amgen in the fourth quarter valued at approximately $1,541,991,000. GAMMA Investing LLC increased its stake in shares of Amgen by 43,573.5% during the first quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company’s stock valued at $1,140,768,000 after acquiring an additional 3,653,205 shares during the period. Capital International Investors increased its stake in shares of Amgen by 40.1% during the fourth quarter. Capital International Investors now owns 12,212,065 shares of the medical research company’s stock valued at $3,182,843,000 after acquiring an additional 3,495,503 shares during the period. Finally, Nuveen LLC bought a new stake in Amgen during the first quarter worth approximately $688,868,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity at Amgen

In related news, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the transaction, the senior vice president directly owned 8,162 shares of the company’s stock, valued at $2,364,368.16. This represents a 15.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.69% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.